Cholesterol Levels are Lowered by ETC-1002 Drug in Hypercholesterolemic Patients

Earlier statistics suggest ETC-1002, a drug that in fact determines oil and carbohydrate metabolic rate, experienced significant impact on levels of cholesterol and improved aspects thought to contribute to cardio-metabolic diseases, say scientists who came from the Methodist DeBakey Heart & Vascular Center, and Esperion Therapeutics Inc., and Baylor College of Medicine, that are showing their task at the 2012 American College of Cardiology Scientific Activity in Chicago.

Briefly outcome using a 12-week phase II clinical trial of three different dosages of ETC-1002, applied day-by-day, suggest a 60 mg daily dose could cause a 27 proportions lowering of LDL cholesterol levels, when compared with a 2 percent reduction in the agency of affected individuals that acquired a placebo. The medication also perceived to influence other parameters that effect cardio-metabolic well-being, for example ApoB, LDL particle number, and non-HDL cholesterols, and did so in a dose-dependent way. Side-effects with the treatment levels studied were identical to those particular for the placebo group.

Principal detective Christie M. Ballantyne, M.D., says further research is required to see the drug's safety at upper doses, and if the drug makes conventional statin therapies more successful. ETC-1002 was created by Roger Newton, who brought the creation of atorvastatin.